Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11121120 | 0.78 | ALDH1A1 (0.31) | ALDH1A1 | |
| SCHEMBL9812763 | 0.75 | — | — | |
| SCHEMBL10900124 | 0.74 | — | — | |
| SCHEMBL1933973 | 0.74 | PTPN1 (0.38) | — | |
| SCHEMBL11408476 | 0.72 | PTPN1 (0.37) | — | |
| SCHEMBL11330951 | 0.72 | — | — | |
| SCHEMBL10830694 | 0.69 | — | — | |
| SCHEMBL5958665 | 0.68 | ALDH1A1 (0.30) | ALDH1A1 | |
| SCHEMBL16326026 | 0.65 | ALDH1A1 (0.34) | ALDH1A1 | |
| SCHEMBL10335060 | 0.65 | ALDH1A1 (0.34) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037320-B2 | Pro-benefit-agent compounds with heterocyclic moieties | THE PROCTER & GAMBLE COMPANY (US) | 2024-07-16 | — | — | US | disclosed |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | THE PROCTER & GAMBLE COMPANY | 2023-07-13 | — | — | US | disclosed |
| US-20230002330-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2023-01-05 | — | — | US | disclosed |
| US-20220177813-A1 | TREATMENT COMPOSITIONS WITH PRO-FRAGRANCE SILICONE POLYMERS THAT COMPRISE HETEROCYCLIC MOIETIES | THE PROCTER & GAMBLE COMPANY | 2022-06-09 | — | — | US | disclosed |
| US-11192904-B2 | Silicone compounds comprising a benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2021-12-07 | — | — | US | disclosed |
| US-20200095267-A1 | SILICONE COMPOUNDS | PROCTER & GAMBLE (US) | 2020-03-26 | — | — | US | disclosed |
| US-10590148-B2 | Silicone compounds comprising a ketone or aldehyde benefit agent moiety | THE PROCTER & GAMBLE COMPANY (US) | 2020-03-17 | — | — | US | disclosed |
| EP-3218425-A1 | SILICONE COMPOUNDS | The Procter and Gamble Company (US) | 2017-09-20 | — | — | EP | disclosed |
| WO-2016077513-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY (US) | 2016-05-19 | — | — | WO | disclosed |
| US-20160137674-A1 | SILICONE COMPOUNDS | THE PROCTER & GAMBLE COMPANY | 2016-05-19 | — | — | US | disclosed |
| EP-2799863-A1 | Method to evaluate fragrance compositions | The Procter and Gamble Company (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-2799864-A1 | Method to evaluate fragrance compositions | The Procter and Gamble Company (US) | 2014-11-05 | — | — | EP | disclosed |
| EP-0266587-B1 | THERMALLY ACTIVATED TWO COMPONENT METATHESIS CATALYST SYSTEM | HERCULES INCORPORATED (US) | 1993-09-08 | — | — | EP | disclosed |
| US-5015705-A | Catalytic polymerization of cycloolefin with tungsten halides, molybdenum halides or oxyhalides and Lewis bases and zinc compounds | HERCULES INCORPORATED (US) | 1991-05-14 | — | — | US | disclosed |
| US-4882401-A | Slow gel/cure systems based on dialkylzinc for dicyclopentadiene polymerization | HERCULES INCORPORATED (US) | 1989-11-21 | — | — | US | disclosed |
| US-4727125-A | NUCLEOPHILIC LEWIS BASES AS REACTION RATE MODIFIERS | HERCULES INCORPORATED (US) | 1988-02-23 | — | — | US | disclosed |
| US-4048147-A | COATINGS, PRINTING INKS, SIZING | JAPAN SYNTHETIC RUBBER CO., LTD. (JA) | 1977-09-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160137674-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885 |
| US-20200095267-A1 | SILICONE COMPOUNDS | SMCHD1, SRI, SMS | ALDH1A1 3917/4885 |
| US-12037320-B2 | Pro-benefit-agent compounds with heterocyclic moieties | PLG, PAM, PREP | ALDH1A1 151/4885 |
| US-10590148-B2 | Silicone compounds comprising a ketone or aldehyde benefit agent moiety | SMN1; SMN2, KARS1, ACADM | ALDH1A1 42/4885 |
| US-20230002330-A1 | PRO-BENEFIT-AGENT COMPOUNDS WITH HETEROCYCLIC MOIETIES | PLG, PAM, PREP | ALDH1A1 151/4885 |
| US-11192904-B2 | Silicone compounds comprising a benefit agent moiety | SMCHD1, SMN1; SMN2, SGMS2 | ALDH1A1 4146/4885 |
| US-20230220300-A1 | TREATMENT COMPOSITIONS WITH MODIFIED AMINO ACID MULTIMERS | BCAT2, MTR, ASNS | ALDH1A1 3811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.